SynthesisClinica chimica acta; international journal of clinical chemistry2020
Comparative analysis of laboratory indexes of severe and non-severe patients infected with COVID-19.
Synthesis in Clinica chimica acta; international journal of clinical chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Pooled it
- Prevalence and clinical outcomes of pleural effusion in COVID-19 patients: A systematic review and meta-analysis.Journal of medical virology · 2022Pooled it
- Early changes in laboratory parameters are predictors of mortality and ICU admission in patients with COVID-19: a systematic review and meta-analysis.Medical microbiology and immunology · 2021Pooled it
- Pooled it
- Pooled it
- Corticosteroids for hospitalized patients with mild to critically-ill COVID-19: a multicenter, retrospective, propensity score-matched study.Scientific reports · 2021Trial
- Differences in the inflammatory response and outcome among hospitalized patients during different waves of the COVID-19 pandemic.Frontiers in immunology · 2025Article
- Eosinopenia predicts poor outcomes in patients with lung cancer with the omicron variant of COVID-19.Frontiers in medicine · 2025Article
- T-cell responses in COVID-19 survivors 6-8 months after infection: A longitudinal cohort study in Pune.Immunity, inflammation and disease · 2024Article
- Coronavirus Disease 2019 Outcomes in Amyloid A Protein Amyloidosis Secondary to Rheumatic Conditions and Signs of Post- Coronavirus Disease 2019 Proteinuria Progression.European journal of rheumatology · 2024Article
- Genetic correlations, shared risk genes and immunity landscapes between COVID-19 and venous thromboembolism: evidence from GWAS and bulk transcriptome data.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2024Article
- Assessing the Association between Biomarkers and COVID-19 Mortality Using the Joint Modelling Approach.Life (Basel, Switzerland) · 2024Article
- The Impact of Effective Vaccination on Clinical and Radiological Involvement in COVID-19 Patients.Medeniyet medical journal · 2023Article
- Long-term oral ACEI/ARB therapy is associated with disease severity in elderly COVID-19 omicron BA.2 patients with hypertension.BMC infectious diseases · 2023Article
- SUPER Score Contributes to Warning and Management in Early-Stage COVID-19.Infectious medicine · 2023Article
- Disproportionate impact of COVID-19 severity and mortality on hospitalized American Indian/Alaska Native patients.PNAS nexus · 2023Article
- A Prognostic Marker in COVID-19 Disease Severity and Mortality: D-Dimer/Platelet Ratio.Cureus · 2023Article
- Equilibrium-based COVID-19 diagnosis from routine blood tests: A sparse deep convolutional model.Expert systems with applications · 2023Article
- Assessing Biomarkers in Viral Infection.Advances in experimental medicine and biology · 2023Review
- Inflammasomes: a rising star on the horizon of COVID-19 pathophysiology.Frontiers in immunology · 2023Review
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe pandemic coronavirus disease 2019 (COVID-19) has threaten the global health. The characteristics of laboratory findings of coronavirus are of great significance for clinical diagnosis and treatment. We found indicators that may most effectively predict a non-severe COVID-19 patient develop into a severe patient.
methodsWe conducted a meta-analysis to compare the laboratory findings of severe patients with non-severe patients with COVID-19 from searched articles.
resultsThrough the analysis of laboratory examination information of patients with COVID-19 from 35 articles (5912 patients), we demonstrated that severe cases possessed higher levels of leukocyte (1.20-fold), neutrophil (1.33-fold), CRP (3.04-fold), PCT (2.00-fold), ESR (1.44-fold), AST (1.40-fold), ALT (1.34-fold), LDH (1.54-fold), CK (1.44-fold), CK-MB (1.39-fold), total bilirubin (1.14-fold), urea (1.28-fold), creatine (1.09-fold), PT (1.03-fold) and D-dimer (2.74-fold), as well as lower levels of lymphocytes (1.44-fold), eosinophil (2.00-fold), monocyte (1.08-fold), Hemoglobin (1.53-fold), PLT (1.15-fold), albumin (1.15-fold), and APTT (1.02-fold). Lymphocyte subsets and series of inflammatory cytokines were also different in severe cases with the non-severe ones, including lower levels of CD4 T cells (2.10-fold) and CD8 T cells (2.00-fold), higher levels of IL-1β (1.02-fold), IL-6 (1.93-fold) and IL-10 (1.55-fold).
conclusionsSome certain laboratory inspections could predict the progress of the COVID-19 changes, especially lymphocytes, CRP, PCT, ALT, AST, LDH, D-dimer, CD4 T cells and IL6, which provide valuable signals for preventing the deterioration of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.